The Ashkenazi Jewish population carries a distinctive genetic signature shaped by centuries of relative reproductive isolation, and that signature extends to the eyes. Several inherited retinal diseases occur at unusually high rates in people of Ashkenazi descent, driven by a small number of founder mutations that became concentrated through population bottlenecks rather than through any adaptive advantage for vision. These conditions range from specific forms of retinitis pigmentosa to the retinal damage caused by lysosomal storage disorders and a rare autonomic nervous system disease that progressively destroys the cells responsible for sight.
Why a Small Population History Matters for Eye Disease
The Ashkenazi Jewish population descends from a group that passed through at least two severe contractions in size. Genetic evidence points to an early bottleneck roughly a hundred generations ago, possibly coinciding with initial migrations from the Near East into Europe, followed by a further contraction between roughly 1100 and 1400 CE.1PubMed. MtDNA evidence for a genetic bottleneck in the early history of the Ashkenazi Jewish population2PubMed Central. A population-genetic test of founder effects and implications for Ashkenazi Jewish diseases After those bottlenecks, the population grew rapidly while remaining largely endogamous, meaning marriages occurred predominantly within the community. The result is higher levels of shared identical-by-descent DNA segments compared to other European populations, along with elevated linkage disequilibrium across the genome.3PubMed Central. Signatures of founder effects, admixture, and selection in the Ashkenazi Jewish population
When a population contracts to a small founding group and then expands, any disease-causing mutations that happened to be present in that founding group can drift to frequencies far higher than they would reach in a large, freely mixing population. That is why certain recessive conditions that are vanishingly rare elsewhere show up at meaningful carrier rates among Ashkenazi Jews. Many of these conditions have consequences for the eyes, because the retina and optic nerve are metabolically demanding tissues especially vulnerable to disruptions in lipid processing, protein trafficking, and neuronal maintenance.
Retinitis Pigmentosa and Ashkenazi-Specific Mutations
Retinitis pigmentosa (RP) is a group of inherited conditions in which the light-sensing photoreceptor cells in the retina gradually die, leading to progressive vision loss that often begins with difficulty seeing in dim light and narrows the visual field over time. RP exists worldwide, but in Ashkenazi Jews, the genetic causes cluster around a remarkably small number of mutations. A study of nonsyndromic RP in the Ashkenazi population found that two mutations together accounted for the vast majority of genetically solved cases: an Alu insertion in the MAK gene was responsible for about 39% of families with a known genetic cause, and a missense mutation in the DHDDS gene accounted for roughly 33%.4PubMed. Nonsyndromic Retinitis Pigmentosa in the Ashkenazi Jewish Population: Genetic and Clinical Aspects
That concentration is striking. In non-Ashkenazi populations, RP can be caused by mutations across more than 80 genes, and no single mutation dominates. In the Ashkenazi population, knowing that two genes explain the lion’s share of cases has direct practical value: it simplifies genetic testing and makes it possible to screen for RP risk using a targeted panel rather than sequencing dozens of genes. It also means that when gene therapies for specific RP subtypes reach maturity, a relatively large proportion of Ashkenazi RP patients could be candidates for a small number of treatments rather than needing highly individualized approaches.
Lysosomal Storage Diseases and the Retina
Some of the best-known Ashkenazi genetic conditions are lysosomal storage disorders, diseases where cells cannot properly break down and recycle certain fats or sugars. The undigested material accumulates inside cells and gradually poisons them. Several of these disorders leave characteristic marks on the retina, sometimes visible even in infancy.
Tay-Sachs Disease
Tay-Sachs disease is perhaps the most widely recognized Ashkenazi genetic condition. It involves the progressive destruction of nerve cells due to the accumulation of a fatty substance called GM2 ganglioside. In the retina, that lipid buildup creates what clinicians call a cherry-red spot: the center of the macula looks bright red against a pale, opaque surrounding retina. The redness is not actually from blood. It is the normal color of the underlying choroid showing through the thin fovea, while the surrounding retinal tissue appears whitened by the engorged, lipid-laden neurons around it. Over time, lipid deposition across all retinal layers contributes to retinal atrophy.5PubMed Central. Long-term follow-up of a Tay-Sachs disease patient with cherry-red spot The cherry-red spot is so consistently present in infantile Tay-Sachs that it became one of the earliest clinical signs used to raise suspicion of the diagnosis.
Niemann-Pick Disease Type A
Niemann-Pick disease type A also involves lipid accumulation, but in this case the problem is with the enzyme acid sphingomyelinase, which normally breaks down a lipid called sphingomyelin. Like Tay-Sachs, it produces cherry-red spots during the first year of life, and the entire retina can take on an opaque appearance as lipid builds up in retinal neurons, light-sensitive receptor cells, and the retinal pigment epithelial cells that support them.6PubMed Central. Retinal Dystrophy and Optic Nerve Pathology in the Mouse Model of Mucolipidosis IV While Niemann-Pick type A is rare even among Ashkenazi Jews, its carrier frequency in this population is high enough to justify inclusion in standard genetic screening panels.
Mucolipidosis Type IV
Mucolipidosis type IV (MLIV) is caused by loss-of-function mutations in the MCOLN1 gene, which encodes a cation channel called mucolipin-1. Without a working channel, lysosomes cannot properly manage their internal environment, and storage material accumulates in cells throughout the body. MLIV is both a neurodevelopmental and a neurodegenerative disorder: affected children show severe delays in motor and cognitive development, and their vision progressively worsens.7PubMed Central. Mucolipidosis type IV: an update The eye findings include corneal clouding, which can begin in infancy, as well as progressive retinal and optic nerve atrophy.6PubMed Central. Retinal Dystrophy and Optic Nerve Pathology in the Mouse Model of Mucolipidosis IV MLIV is almost exclusively found in people of Ashkenazi ancestry, making it one of the most population-specific eye diseases known.
Familial Dysautonomia and Progressive Blindness
Familial dysautonomia (FD) is a rare autosomal recessive disorder caused by a splicing mutation in the ELP1 gene, previously known as IKBKAP. The mutation causes the cellular machinery to skip a critical segment of the gene’s instructions, reducing production of the ELP1 protein in the central and peripheral nervous system.8PubMed Central. Selective retinal ganglion cell loss and optic neuropathy in a humanized mouse model of familial dysautonomia FD is best known for its effects on the autonomic nervous system, causing problems with blood pressure regulation, temperature control, swallowing, and pain perception. But one of the most debilitating symptoms for patients’ daily lives is progressive blindness resulting from steady loss of retinal ganglion cells (RGCs), the neurons that carry visual information from the eye to the brain.9PubMed Central. Neuronal and glial cell alterations involved in the retinal degeneration of the familial dysautonomia optic neuropathy
Research using a humanized mouse model of FD has confirmed that the thinning of the retinal nerve fiber layer and the ganglion cell-inner plexiform layer seen on clinical imaging scans directly reflects a progressive loss of RGCs that worsens with age.8PubMed Central. Selective retinal ganglion cell loss and optic neuropathy in a humanized mouse model of familial dysautonomia This matters because the optic neuropathy in FD is not a secondary complication. It appears to be a core feature of the disease’s neurodegeneration, raising the possibility that retinal imaging could serve as an accessible biomarker for tracking disease progression across the nervous system more broadly. Since FD occurs almost exclusively among Ashkenazi Jews, with carrier frequencies estimated at roughly 1 in 30, the retinal component of this disease is relevant to anyone of Ashkenazi descent undergoing genetic counseling or carrier screening.
Age-Related Macular Degeneration
Not every eye condition with a genetic component in Ashkenazi populations involves rare monogenic disorders. Age-related macular degeneration (AMD), the leading cause of vision loss in older adults worldwide, has a substantial genetic component, and researchers have investigated whether Ashkenazi Jews carry distinctive risk profiles. A study looking at rare genetic variants in Jewish patients with AMD found that common risk variants in two well-known AMD-associated genes, CFH and ARMS2, appeared at frequencies compatible with those seen in the general population.10PubMed Central. Rare Genetic Variants in Jewish Patients Suffering from Age-Related Macular Degeneration The more interesting finding was the hypothesis that rare variants, rather than the common ones already known, may contribute more to disease risk than previously appreciated.
This is an area where the genetics of the Ashkenazi population could prove especially useful for research. Because of the founder effect, rare variants that exist at extremely low frequencies in other populations can appear at slightly higher frequencies among Ashkenazi Jews, making them easier to detect in gene-association studies. In that sense, the Ashkenazi population functions as a natural magnifying glass for identifying genetic contributors to complex diseases like AMD, potentially benefiting treatment and risk-assessment models for everyone.
How Ancient Are These Disease Alleles?
Until recently, researchers debated exactly when the Ashkenazi founder mutations reached appreciable frequencies. A breakthrough came from ancient DNA recovered from a medieval mass burial in Norwich, England. The remains, consistent with victims of a historically attested antisemitic massacre in 1190 CE, showed strong genetic affinities with modern Ashkenazi Jews. Crucially, four alleles associated with Ashkenazi genetic diseases were identified in these individuals, and simulations based on the findings suggested that disease-associated alleles were already at substantial frequencies centuries earlier than previously assumed.11PubMed Central. Genomes from a medieval mass burial show Ashkenazi-associated hereditary diseases pre-date the 12th century The researchers also inferred pigmentation traits from the DNA, including red hair, illustrating that the genetic profile of medieval Ashkenazi communities was already recognizably similar to the modern population.
Separate genome-wide analysis of medieval Ashkenazi remains from Germany reinforced the conclusion that the founder event and the main sources of Ashkenazi ancestry predated the fourteenth century, though it also revealed late medieval genetic heterogeneity that has since been lost in the modern population.12PubMed Central. Genome-wide data from medieval German Jews show that the Ashkenazi founder event pre-dated the 14th century For eye-related conditions, this means the mutations behind disorders like Tay-Sachs, familial dysautonomia, and potentially the RP-causing alleles have been drifting at elevated frequencies within this population for at least eight or nine centuries, and possibly longer.
The Case for Expanded Carrier Screening
Carrier screening panels for Ashkenazi genetic diseases have existed since the 1970s, when Tay-Sachs screening programs dramatically reduced the birth incidence of the disease. But the traditional screening approach tested for a limited number of the best-known conditions. A study screening Ashkenazi college students found that when testing was limited to the classic narrow panel, 84% of the mutations identified by expanded testing would have gone undetected. Even a moderately expanded panel would have missed more than half.13PubMed Central. Beyond the “Jewish panel”: the importance of offering expanded carrier screening to the Ashkenazi Jewish population In this cohort, about 44% of individuals screened turned out to be carriers for at least one condition, and some carried mutations for more than one disease.
For eye health specifically, this matters because several of the conditions with retinal consequences, such as MLIV and the rarer lysosomal storage diseases, were not always included in older panels. Someone who tested negative on a basic Tay-Sachs and cystic fibrosis screen might not realize they carry a mutation for MLIV, familial dysautonomia, or one of the Ashkenazi-specific RP genes. Expanded carrier screening can identify these risks before family planning, giving couples the information to pursue genetic counseling, prenatal testing, or preimplantation genetic diagnosis if they choose.
Myopia Genetics in Ashkenazi Families
Myopia, or nearsightedness, is one of the most common vision problems in the world, and it runs in families. Because the Ashkenazi population has relatively high rates of myopia and offers genetic advantages for linkage studies due to its founder-effect history, researchers have used Ashkenazi families to hunt for myopia susceptibility genes. An ordered subset analysis of Ashkenazi Jewish families with myopia found strong evidence of a linked region on chromosome 20, along with suggestive signals on chromosomes 11 and 6.14PubMed Central. Dissecting the genetic heterogeneity of myopia susceptibility in an Ashkenazi Jewish population using ordered subset analysis None of these loci have yielded a single causative gene, reflecting the complex, polygenic nature of common myopia: dozens or hundreds of gene variants each contribute a small amount to risk.
The significance of these findings lies less in any immediate clinical use and more in the research strategy. Because the Ashkenazi founder effect reduces genetic noise, it is sometimes easier to spot weak signals of linkage in this population than in more genetically heterogeneous groups. Myopia susceptibility loci mapped in Ashkenazi families have helped refine the broader map of myopia genetics for all populations, even though the underlying biology is shared across ancestries.
Pharmacogenomics and Anti-VEGF Therapy for AMD
As treatment for wet AMD has become increasingly reliant on injections of anti-VEGF drugs into the eye, researchers have begun investigating whether a patient’s genotype predicts how well they respond. Studies have found associations between genotypes at the CFH, ARMS2, HTRA1, and VEGF-A genes and outcomes after anti-VEGF treatment, with patients carrying lower-risk genotypes tending to have better visual results. The frequency of injections needed may also vary by genotype.15PubMed Central. Pharmacogenomics of response to anti-VEGF therapy in exudative age-related macular degeneration
This is still early-stage work, and no ophthalmologist currently tailors anti-VEGF dosing based on a genetic test. But if pharmacogenomic approaches mature, the well-characterized genetic profiles available in the Ashkenazi population could help validate predictive models. Because common AMD risk variants in Ashkenazi Jews appear at frequencies similar to those in the broader population, any pharmacogenomic tool validated there would likely generalize well. The greater interest, again, lies in rare variants: if rare alleles contribute meaningfully to AMD risk and treatment response, and if those alleles are somewhat enriched in the Ashkenazi population due to founder effects, this group could offer an efficient setting for discovery studies.
Inherited Retinal Disease in Other Jewish Communities
While the Ashkenazi population gets the most attention in discussions of Jewish genetic disease, other Jewish communities have their own distinct founder mutations affecting vision. A study of inherited retinal diseases among Israeli Jews of Ethiopian ancestry identified seven distinct mutations in the ABCA4 gene, which causes Stargardt disease and other retinal dystrophies. The most common of these, c.6077delT, appeared on about 36% of ABCA4-mutant chromosomes in the cohort and is absent from all major public genetic databases, making it a likely unique founder mutation of the Ethiopian Jewish population.16PubMed Central. Genetic causes of inherited retinal diseases among Israeli Jews of Ethiopian ancestry
This finding is a useful reminder that “Jewish genetic diseases” are not a monolith. Each Jewish diaspora community experienced its own bottlenecks, its own periods of isolation, and its own accumulation of founder mutations. The clinical takeaway is that ethnicity-based screening panels designed around Ashkenazi mutations will miss conditions prevalent in Sephardi, Mizrahi, or Ethiopian Jewish communities. Any serious approach to genetic screening in diverse Jewish populations needs community-specific data, not a one-size-fits-all panel built on Ashkenazi genetics alone.
Retinal Imaging as a Window Into Neurodegeneration
One thread connecting several Ashkenazi-associated conditions is that the retina serves as an accessible proxy for neurodegeneration happening deeper in the nervous system. In familial dysautonomia, thinning of the retinal nerve fiber layer tracks the loss of ganglion cells that defines the disease’s optic neuropathy. In MLIV, retinal atrophy progresses alongside broader neurological decline. Even in optic neuritis, a condition not specific to any ethnic group, researchers have shown that decreased vascular density in the retina correlates with ganglion cell layer thinning, and these changes appear not just in the affected eye but in the fellow eye as well.17PubMed Central. Retinal Vascular Density Using Optical Coherence Tomography-Angiography in Optic Neuritis
The retina is the only part of the central nervous system that can be directly imaged without surgery. Technologies like optical coherence tomography and OCT-angiography now measure retinal layer thickness and blood vessel density with micrometer precision. For Ashkenazi patients with conditions that include neurodegeneration, these tools offer a noninvasive way to monitor disease progression over time, to assess response to experimental treatments, and potentially to detect subclinical disease before symptoms appear. As gene therapies and small-molecule treatments advance for conditions like FD and MLIV, having a reliable, repeatable imaging biomarker in the eye could accelerate clinical trials by providing measurable endpoints that do not require years of follow-up for neurological decline.